The influence of type of inhalation device on adherence of COPD patients to inhaled medication

ABSTRACT Objective: To study the influence of type of inhalation device on medication adherence of COPD patients. Methods: Adherence to inhalation medication of 795 patients was recorded from pharmacy records over 3 years. It was expressed as percentage and deemed good at ≥75–≤125%, sub-optimal ≥50–<75%, and poor <50% (underuse) or >125% (overuse). Since most patients used more than one device, 1379 medication periods were analyzed. Results: Patients using a Metered Dose Inhaler (MDI) or Diskus had a 2.3-fold and 2.2-fold increased risk, respectively, of suboptimal adherence versus good adherence, compared to Handihaler and a 2.1-fold and 2.2-fold increased risk, respectively, of underuse versus good adherence compared to Handihaler. Turbuhaler, MDI, Respimat had a 7.9-fold, 3.5-fold, and 2.0-fold increased risk, of overuse versus good adherence compared to Handihaler. Conclusions: In COPD, adherence to inhalation medication is device-related. Overuse was most pronounced for devices without a dose counter, devices with the ability to load a dosage without actual inhalation, or devices lacking feedback of correct inhalation. The design of the device seems to be related to underuse and overuse of inhaled medication. Future research might investigate whether prescribing a different device with similar medication improves therapy adherence.

[1]  J. George,et al.  Factors associated with medication nonadherence in patients with COPD: Chest 2005;128:3198–204 , 2006 .

[2]  F. Lavorini,et al.  Targeting drugs to the airways: The role of spacer devices. , 2009, Expert opinion on drug delivery.

[3]  J. van der Palen,et al.  Differences in Adherence to Common Inhaled Medications in COPD , 2013, COPD.

[4]  R. Negro.  Dry powder inhalers and the right things to remember: a concept review , 2015 .

[5]  R. van der Lende,et al.  [Prevalence of cold in Vlagtwedde and Vlaardingen (computer diagnosis versus doctors' diagnosis)]. , 1975, Nederlands tijdschrift voor geneeskunde.

[6]  D. Haupt,et al.  Medication persistence among patients with asthma/COPD drugs , 2008, Pharmacy World & Science.

[7]  J A Anderson,et al.  Adherence to inhaled therapy, mortality and hospital admission in COPD , 2009, Thorax.

[8]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[9]  J. Bourbeau,et al.  Patient adherence in COPD , 2008, Thorax.

[10]  J. L. Rau,et al.  Practical problems with aerosol therapy in COPD. , 2006, Respiratory care.

[11]  R. Barrons,et al.  Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[13]  Matteo Bonini,et al.  Why do doctors and patients not follow guidelines? , 2009, Current opinion in allergy and clinical immunology.

[14]  J. van der Palen,et al.  Preference, satisfaction and errors with two dry powder inhalers in patients with COPD , 2013, Expert opinion on drug delivery.

[15]  C. van Weel,et al.  Compliance During Long-Term Treatment with Fluticasone Propionate in Subjects with Early Signs of Asthma or Chronic Obstructive Pulmonary Disease (COPD): Results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study , 2000, The Journal of asthma : official journal of the Association for the Care of Asthma.

[16]  V. Backer,et al.  Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. , 2013, Respiratory medicine.

[17]  H. Chrystyn,et al.  Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. , 2014, Respiratory medicine.

[18]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[19]  L. Ring,et al.  Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10‐year period , 2007, Journal of clinical pharmacy and therapeutics.

[20]  P. Chanez,et al.  Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases , 2014, Therapeutic advances in chronic disease.

[21]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[22]  Chris Corrigan,et al.  Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. , 2008, Respiratory medicine.

[23]  K. Alzoubi,et al.  Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. , 2008, Respiratory care.

[24]  Rishi Sikka,et al.  Estimating medication persistency using administrative claims data. , 2005, The American journal of managed care.

[25]  C. Rand,et al.  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. , 1999, Medical care.

[26]  E. Meltzer,et al.  Patient Satisfaction with a Pressurized Metered-Dose Inhaler with an Integrated Dose Counter Containing a Fixed-Dose Mometasone Furoate/Formoterol Combination , 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.

[27]  D. Au,et al.  Adherence to Long-Acting Inhaled Therapies among Patients with Chronic Obstructive Pulmonary Disease (COPD) , 2012, COPD.

[28]  D. Shaw,et al.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[29]  R. D. Dal Negro.  Dry powder inhalers and the right things to remember: a concept review , 2015, Multidisciplinary Respiratory Medicine.

[30]  D. Tashkin.  Multiple dose regimens. Impact on compliance. , 1995, Chest.

[31]  W. Boersma,et al.  Adrenomedullin optimises mortality prediction in COPD patients. , 2015, Respiratory medicine.

[32]  Marco Lodi,et al.  Inhaler mishandling remains common in real life and is associated with reduced disease control. , 2011, Respiratory medicine.